RARE vs RMD · rev $350.0M vs P/E 29, rev $5.65B
Ultragenyx (RARE) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
RARE currently screens at market cap $2.79B. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the RARE and RMD stock pages for the full models.
Not investment advice.